financetom
Business
financetom
/
Business
/
BMO on The Day Ahead in Canada
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BMO on The Day Ahead in Canada
Aug 7, 2024 4:50 AM

07:20 AM EDT, 08/07/2024 (MT Newswires) -- Bank of Canada (BoC) will release the Summary of Deliberations of the July 24 policy meeting, which saw a second consecutive 25 bps rate cut, at 1:30 p.m. ET on Wednesday, noted Bank of Montreal (BMO).

The Summary will be parsed to assess whether the BoC's extremely dovish tone was fully intentional, stated the bank. The policy statement, along with Governor Tiff Macklem's opening remarks and press conference, signaled that risks to the outlook are more balanced and that the incoming data will have to keep the BoC from cutting, rather than prompt the Canadian central bank to cut.

BMO will be looking for confirmation of the change in posture, and any hints on how far the BoC intends to ease policy. Lastly, markets will be watching closely for any thoughts on the Canadian dollar (CAD or loonie) and potential deviation from the United States Federal Reserve.

Also, the economy-wide Ivey PMI for July will be released at 10 a.m. ET Wednesday. In June, it was 62.5. The continued indication of economic growth (50+) reflects the rapid rise in population, pointed out the bank.

The US dollar (USD) is firmer (BBDXY +0.11%), with the loonie also stronger (CAD per USD -0.28%) early Wednesday, according to BMO.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update: Moderna Shares Dropped After Q2 Results
Update: Moderna Shares Dropped After Q2 Results
Aug 1, 2024
01:02 PM EDT, 08/01/2024 (MT Newswires) -- (Updates to add stock move in the headline and the first paragraph.) Moderna ( MRNA ) shares dropped nearly 21% in recent Thursday trading after the company reported its results for Q2. The company reported a Q2 loss Thursday of $3.33 per diluted share, narrowing from a loss of $3.62 a year earlier....
Littelfuse Insider Sold Shares Worth $1,037,079, According to a Recent SEC Filing
Littelfuse Insider Sold Shares Worth $1,037,079, According to a Recent SEC Filing
Aug 1, 2024
01:00 PM EDT, 08/01/2024 (MT Newswires) -- David W Heinzmann, Director, President & CEO, on July 31, 2024, sold 3,786 shares in Littelfuse ( LFUS ) for $1,037,079. Following the Form 4 filing with the SEC, Heinzmann has control over a total of 59,654 shares of the company, with 59,654 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/889331/000088933124000163/xslF345X03/form4.xml Price: 256.34, Change: -10.78,...
Lilly CEO says weight-loss drug shortage to end 'very soon', Bloomberg News reports
Lilly CEO says weight-loss drug shortage to end 'very soon', Bloomberg News reports
Aug 1, 2024
Aug 1 (Reuters) - U.S. drugmaker Eli Lilly ( LLY ) expects its blockbuster weight-loss drug to officially come out of shortage in the United States in coming days, Bloomberg News reported on Thursday, citing an interview with the company's chief executive officer, David Ricks. Lilly's drug, tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight management, will cease...
Arbutus Biopharma to Reduce Workforce by 40% to Focus on Hepatitis B Treatment Imdusiran
Arbutus Biopharma to Reduce Workforce by 40% to Focus on Hepatitis B Treatment Imdusiran
Aug 1, 2024
01:02 PM EDT, 08/01/2024 (MT Newswires) -- Arbutus Biopharma ( ABUS ) said Thursday that it is cutting its workforce by 40% to focus its resources on imdusiran, which is intended to reduce all hepatitis B viral antigens. We intend to focus our existing resources on conducting a phase 2b clinical trial with imdusiran, assuming continued positive data, the company...
Copyright 2023-2026 - www.financetom.com All Rights Reserved